G Kees Hovingh (1974) received his medical degree at the University of Groningen in 2000, his PhD in 2005 and his MBA in 2016.
During his PhD (supervisor: prof dr John Kastelein) Hovingh focussed on unraveling the causes and consequences of inherited disorders in lipid metabolism. He interrupted his subsequent medical specialist training to work as a post-doc at the department of genetics under direct supervision of profs. Jon and Kricket Seidman, where he dedicated his time on projects focused on sub-genome capture for next generation sequencing.
Hovingh is a full professor, internist, and vascular medicine specialist at the Department of Vascular Medicine at the Amsterdam University Medical Center (location AMC) of the University of Amsterdam, the Netherlands. He also was awarded a visiting professorship at Imperial college in London, UK in 2015.
Hovingh has served as co-chair of the department of internal medicine at the AMC from 2017 to 2019. Moreover, he was as head of the clinical trial unit involved in a large number of clinical trials from 2011 to 2019, where his team mainly focused on the execution of clinical trials novel therapies to combat (the consequences of) dyslipidemia, venous thrombosis, NASH and hemophilia.
Hovingh co-authored over 300 publications (web of science Hirsh factor: 74; pubmed search term “Hovingh G OR Kees Hovingh OR Hovingh K”) and has given numerous lectures, mainly about dyslipidemia and atherosclerosis. Hovingh has received a number of personal grants (VENI and VIDI grant provided by ZonMW) and collaborative grants (a.o. LeDucq, EU Eureka, FP7)
Since april 2019, Hovingh is partly employed by Novo Nordisk, Copenhagen (70%) where he serves as Senior Medical officer, reporting directly to the CMO. Hovingh was appointed to increase the cardiovascular portfolio in Novo Nordisk and in the first year of his appointment he was co-lead of the due diligence that ultimately led to the acquisition of Corvidia (main asset: ziltivikemab, an IL6ligand inhibitor)